Loading…
Lobbying Spend
—
Filings
6
Firms Hired
1
Active Period
2015–2016
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Advancing Targeted Therapies for Rare Diseases Act of 2016
2016 · third_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Education around the science and therapeutic potential of gene editing technology. S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2016
Client expense: — · Firm income: —
Matched citations: S.2030
Advancing Targeted Therapies for Rare Diseases Act of 2016
2016 · third_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Education around the science and therapeutic potential of gene editing technology. S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2016
Client expense: — · Firm income: —
Matched citations: S.2030
Advancing Targeted Therapies for Rare Diseases Act of 2016
2016 · second_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Education around the science and therapeutic potential of gene editing technology. S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2016
Client expense: — · Firm income: $20,000
Matched citations: S.2030
Advancing Targeted Therapies for Rare Diseases Act of 2016
2016 · second_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Education around the science and therapeutic potential of gene editing technology. S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2016
Client expense: — · Firm income: $20,000
Matched citations: S.2030
Advancing Targeted Therapies for Rare Diseases Act of 2016
2016 · first_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Education around the science and therapeutic potential of gene editing technology. S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2016
Client expense: — · Firm income: $20,000
Matched citations: S.2030
Advancing Targeted Therapies for Rare Diseases Act of 2016
2016 · first_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Education around the science and therapeutic potential of gene editing technology. S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2016
Client expense: — · Firm income: $20,000
Matched citations: S.2030
Source: Senate LDA